Skip to main content
. Author manuscript; available in PMC: 2018 Mar 13.
Published in final edited form as: Bone Marrow Transplant. 2016 Sep 5;52(1):28–33. doi: 10.1038/bmt.2016.204

Figure 1.

Figure 1

Figure 1a. Improved overall survival rate in CLL patients after non-myeloablative allogeneic transplantation with bendamustine, fludarabine, and rituximab conditioning (upper curve) vs. findings with fludarabine, cyclophosphamide, and rituximab conditioning (lower curve).

Figure 1b. Overall survival rate in patients with CLL associated with 17p deletion after non-myeloablative allogeneic transplantation with bendamustine, fludarabine, and rituximab conditioning (upper curve) vs. findings with fludarabine, cyclophosphamide, and rituximab conditioning (lower curve).

Figure 1c. Overall survival rate in patients with CLL after non-myeloablative allogeneic transplantation according to the use of ATG.